Treatments Research

Table of Contents

There are many Lupus treatment research projects currently being conducted. Below are links to more information about many of them.

MedImmune - Medi-545 is an antibody that targets Interferon-alpha.  It has been in Phase 2A trials since Aug. 2008.  more...

Genentech - Rontalizumab, an antibody targeting Interferon-alpha is in Phase II trials.

Immunomedics, Inc. - Epratuzamab an anti-CD22 antibody announced positive data in a Phase IIb study.  Phase III testing planned.  more...

ImmuPharma - Lupuzor has successfully completed phase I, Phase IIa and Phase IIb studies and is now in preparation for phase III.  has a novel mechanism of action aimed at modulating the body’s immune system so it does not attack healthy cells without causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.  In May 2010 it was announced that Phase III testing to begin within weeks.  more...

Merck Serono - Atacicept (TACI-Ig) in 2 Phase II/III trials.  Atacicept is an anti-BLyS, anti-APRIL protein.

La Jolla Pharmaceuticals - Abetimus sodium, LJP 394, Rentol, Riquent is an anti B cell therapy in ongoing Phase III trials.

Trubion Pharmaceuticals/Wyeth - Phase I clinical trial of SBI-087 for SLE was started in March of '09, SBI-087 targets CD-20 more info...

Neovacs - Begining Phase I/II trials w/ their Interferon alpha (IFN?) Kinoid in lupus patients.  TNF?-K, IFN?-K and VEGF-K are the candidates.  more info...

Amgen - Anti-interferon gamma antibody, AMG811 started a Phase Ib trial in Mar. 2009. more...

Amgen - AMG557 is an anti-T cell antibody.  AMG557 is currently in Phase I trials. more...

Active Biotech - Paquinimod (ABR-215757) is an oral compound used to regulate the immune system in SLE.  It completed a Phase Ib trial and is conducting Phase II/III trials.  more...

Stem Cell Transplants - There are currently several studies being conducted on stem cell transplants in Lupus.  One by Nanjing Medical University in China, one by Duke University in North Carolina, another is being conducted at Stanford University in California, there is one in Germany, and another at Northwestern University in Chicago.  Fred Hutchinson Cancer Research Center in Washington D.C. has also initiated a study on this procedure in children. 

Anthera Pharmaceuticals Inc. - A-623 is an inhibitor to B-Cell Activating Factor (BAFF).  In July of 2010 a Phase IIb study was initiated. more... December 1st it was announced that enrollment and dosing was halted due to cracked vials of the product.  more... January 11th Anthera annouced they were resuming their Phase IIb study. more...

SuppreMol - SM101 is a recombinant, soluble, nonglycosylated version of the Fc gamma (Fcγ) receptor IIb.  SuppreMol recieved a $2.1 Million grant from the German Federal Ministry of Education and Research to support further development.  more...

Argos - AGS-009 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with the ability to bind and neutralize human interferon alpha (IFN-alpha).  Phase I trials were initiated in Dec. 2010.  more... 

Idera Pharmaceuticals - IMO-3100 is a TLR7 and TLR9 antagonist shown to inhibit disease development in mice with Lupus. Phase I studies have been conducted. more... 

See also: Clinical Trials, SLE Genetic Studies, Government Research & Online Lupus Studies